Up Therapeutics

UP Therapeutics is a South Korean biotechnology company specializing in the development of first-in-class small molecule therapeutics targeting cancer metabolism. The company's core strategy focuses on inhibiting mitochondrial complex I to deplete the energy resources of cancer cells, particularly those that are resistant to conventional therapies. Their lead candidate, UP-101, is currently being evaluated in clinical trials for the treatment of glioblastoma and other advanced solid tumors. UP Therapeutics leverages its proprietary metabolic profiling platform to identify and validate novel targets within the tumor microenvironment. By focusing on metabolic reprogramming, the company aims to overcome drug resistance and provide new options for patients with aggressive cancers. The company was founded by experts in oncology and metabolism and has secured significant venture capital funding to advance its clinical programs.